Go to deals

Avacta Group has raised funds via a placing and subscription to both institutional and retail investors

Avacta Group Plc has raised US$60.3 million to continue developing next generation cancer therapies.

Avacta’s mission is to shape the future of medicine by developing safe and efficacious drugs and powerful research and diagnostic tools. Avacta is developing novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre|CISIONTM tumor-targeted chemotherapy. With this approach, the company aims to address the lack of a durable response to current immunotherapies experienced by most patients.

Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as financial advisor and broker, assisting Avacta’s management team and shareholders all the way from the start to the successful completion of the fundraising. During this process, the team initiated and advised on many aspects, including, among others, securing pre-commitments from both existing and new institutional investors, deal structuring, document preparation and the fundraise pricing and sizing.

Funding, debt advisory & ECM

Talk to the deal team

 Geoff  Nash

Geoff Nash

London, United Kingdom
Oaklins Cavendish

Related deals

SulAmérica and Rede D’Or São Luiz have announced a combination
Financial Services | Healthcare

SulAmérica and Rede D’Or São Luiz have announced a combination

SulAmérica (B3:SULA11), a leading insurance company in Brazil, has announced a combination with Rede D’Or São Luiz S.A. (B3:RDOR3), the largest Brazilian hospital network. The companies had a combined market value of approximately US$21 billion on 18 February 2022.

Learn more
Change Financial (ASX:CCA) has raised US$4 million
Financial Services

Change Financial (ASX:CCA) has raised US$4 million

Change Financial has completed a capital raise to help accelerate product enhancement, repay its debt, provide working capital and cover the costs of the offer.

Learn more
Agar Scientific has been acquired by Calibre Scientific
Private Equity | Healthcare

Agar Scientific has been acquired by Calibre Scientific

Agar Scientific Ltd. (Agar) has been sold to Molecular Dimensions Limited, a subsidiary of Calibre Scientific, Inc., a US-based life sciences company, owned by international private investment firm StoneCalibre.

Learn more